Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model by van Vlerken, Lilian E. et al.
Biodistribution and Pharmacokinetic Analysis of
Paclitaxel and Ceramide Administered in Multifunctional
Polymer-Blend Nanoparticles in Drug Resistant Breast
Cancer Model
Lilian E. van Vlerken,
† Zhenfeng Duan,
‡ Steven R. Little,
§ Michael V. Seiden,
|
and Mansoor M. Amiji*
,†
Department of Pharmaceutical Sciences, Northeastern UniVersity, Boston, Massachusetts,
Department of Orthopedic Surgery, Massachusetts General Hospital, Boston,
Massachusetts, Department of Chemical Engineering, UniVersity of Pittsburgh, Pittsburgh,
PennsylVania, and Fox Chase Cancer Center, Philadelphia, PennsylVania
Received February 27, 2008; Revised Manuscript Received June 16, 2008; Accepted June 18, 2008
Abstract: In this study, we have investigated the biodistribution and pharmacokinetic analysis
of paclitaxel (PTX) and the apoptotic signaling molecule, C6-ceramide (CER), when administered
in a multifunctional polymer-blend nanoparticle formulation to female nude mice bearing an
orthotopic drug sensitive MCF7 and multidrug resistant MCF7TR (MDR-1 positive) human breast
adenocarcinoma. A polymer-blend nanoparticle system was engineered to incorporate temporally
controlled sequential release of the combination drug payload. Hereby, PTX was encapsulated
in the pH-responsive rapid releasing polymer, poly(beta-amino ester) (PbAE), while CER was
present in the slow releasing polymer, poly(D,L-lactide-co-glycolide) (PLGA) within these blend
nanoparticles. When particle formulations were administered intravenously to MCF7 and MCF7TR
tumor bearing mice, higher concentrations of PTX were found in the blood due to longer retention
time and an enhanced tumor accumulation relative to administration of free drug. In addition,
the PLGA/PbAE blend nanoparticles were effective in enhancing the residence time of both
drugs at the tumor site by reducing systemic clearance. Overall, these results are highly
encouraging for development of multifunctional polymer-blend nanoparticle formulations that
can be used for temporal-controlled administration of two drugs from a single formulation.
Keywords: Multidrug resistant tumors; polymer-blend nanoparticles; paclitaxel; ceramide;
biodistribution; noncompartmental pharmacokinetics
Introduction
A major clinical obstacle in cancer therapy is the develop-
ment of resistance to a multitude of chemotherapeutic agents,
a phenomenon termed multidrug resistance (MDR).
1 The
development of drug resistance in a small subset of tumor
cells is believed to be the cause for tumor survival despite
invasive chemotherapy. Chemoresistance can generally result
from either of two means: (1) by physically impairing
delivery to the tumor
2 (e.g., poor absorption, increased
metabolism/excretion, and/or poor diffusion of drugs into
the tumor mass) or (2) through intracellular mechanisms that
raise the threshold for cell death.
3–5 The latter is commonly
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Published on Web 07/11/2008implicated in the development of MDR, and, often, more
than one mechanism, either simultaneous or sequential, may
be responsible for the MDR phenotype.
1,4 The most fre-
quently occurring causes of MDR include overexpression
of membrane-bound ATP-dependent drug efﬂux pumps from
the ABC transporter family (most notably P-glycoprotein/
MDR-1), modiﬁcations in drug metabolism through glu-
tathione-S-transferase or cytochrome P450 activity, alter-
ations in DNA repair mechanisms, and critical alterations
in the cellular apoptotic signaling mechanisms.
1,3,5
For this purpose, we have hypothesized that a multifunc-
tional nanoparticle-based therapeutic strategy would be
beneﬁcial for the treatment of MDR tumor, especially with
the use of combination strategies that evade efﬂux transport
and lower the tumor apoptotic threshold.
6,7 Based on the
principle that MDR has been shown to result from metabo-
lism of the apoptotic mediator ceramide by the enzyme
glucosylceramide synthase (GCS) to elevate the apoptotic
threshold,
8–11 this novel therapeutic strategy aims to restore
the alternation in the cellular apoptotic signaling through a
combination therapy of paclitaxel (PTX), a microtubule
stabilizing agent and promoter of apoptosis, and exogenous
C6-ceramide (CER), which can propagate apoptotic signaling
and allow for enhanced cell-kill response.
Based on preliminary evidence, it was found that a
combination therapy of PTX with CER is most effective
against MDR breast and ovarian cancer when CER is
administered with a time delay (typically 6 h) following PTX
administration. To incorporate this temporal spacing of drug
release, a polymer-blend nanoparticle was designed by
blending 70% by weight poly(D,L-lactic-co-glycolic acid)
(PLGA) to 30% by weight poly(beta-amino ester) (PbAE)
to control release of the PTX + CER combination therapy
for optimal therapeutic efﬁcacy. This strategy was conceived
based on earlier work of Little et al.,
12 where PLGA/PbAE
blend microspheres were used for DNA vaccine delivery in
antigen presenting cells. A large library (>5,000) of poly-
(beta-amino esters) (PbAEs) has been synthesized and
evaluated for cellular toxicity and transfection potential, by
reacting diol-diacrylates with various types of primary and
secondary amines.
13,14 A representative hydrophobic PbAE,
synthesized by the addition reaction of 4,4′ -trimethyldipip-
eridine with 1,4-butanediol diacrylate, has unique pH-
solubility properties; the polymer remains intact at pH 7.4,
but rapidly dissolves at pH 6.5.
13 This PLGA/PbAE blend
nanoparticle was designed to immediately release PTX by
rapid dissolution of PbAE in a lower pH environment, such
as the tumor microenvironment (pH < 6.5), or in the
endosome/lysosome of a cell following internalization.
Conversely, CER was expected to exhibit slower release
(being localized with the pH-insensitive polymer, PLGA),
facilitating cellular apoptosis. From previous studies, we have
observed that the exogenously administered CER reinstates
the apoptotic signal to resensitize the cancer cells to the
chemotherapeutic drug PTX.
6 Additionally, long-circulating,
nanoparticle-based, systemic delivery of the combination
therapy enhances efﬁcacy at the cellular level by increasing
intracellular drug accumulation and optimizing the dose
administered, and on a whole body level by increasing
targeting and residence time of the drug at the tumor mass
upon systemic administration.
15–17
Site-speciﬁc drug delivery systems increase the therapeutic
beneﬁt by delivering a greater fraction of the dose at the
target site, which minimizes the amount of therapeutic that
accumulates at nonspeciﬁc targets. Drug delivery throughout
the tumor mass is crucial for the treatment to be effective,
since residual cancer cell survival can promote regrowth and
often becomes the cause for drug resistance.
18 For colloidal
carriers, such as liposomes and polymeric nanoparticles, these
barriers can be overcome through the unique properties of
tumor neovasculature.
19 Angiogenesis (the formation of new
vasculature) associated with rapid growth of the tumor mass
results in fenestrations in tumor capillaries.
20 These fenestra-
tions (or gaps between adjacent endothelial cells), are sized
around 200-400 nm.
20 In addition, the lymphatic system,
which usually runs alongside the blood circulation to clear
macromolecules from tissues, is impaired in solid tumors.
This lack of lymphatic drainage results in decreased clearance
of macromolecules (>40 kDa) within the vicinity of the
tumor.
20 Together, these two physiologic parameters of the
tumor mass, termed the enhanced permeability and retention
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20 can be taken advantage of to improve drug
delivery to tumors mediated by nanocarriers.
Previous studies from our group have shown that paclitaxel
(PTX)-containing PEO-PCL nanoparticles remain stable in
ViVo, and retain the PEO copolymer (Pluronic) surface layer
to increase the circulating half-life and plasma residence time
of PTX from a fraction of an hour to 25.3 and 24.0 h,
respectively, alongside a nearly 8-fold decrease in total body
clearance of the drug.
16,21 The concentration of PTX inside
the tumor mass of mice-bearing human ovarian carcinoma
(SKOV3) xenografts, as a result, was 8.7-fold higher 5 h
postinjection as compared to mice treated with paclitaxel
solution,
16 resulting in enhanced therapeutic efﬁcacy of the
nanoparticle formulation over solution PTX, seen by the 63%
reduction of ﬁnal tumor volume.
15
To examine the effectiveness of PEO-modiﬁed PLGA/
PbAE blend nanoparticles for improving the tumor ac-
cumulation of the PTX + CER drug load, as a means toward
enhanced efﬁcacy, we have administered the control and test
formulations to mice bearing drug sensitive (MCF7) and
MDR (MCF7TR) human breast tumor xenografts. In this
study, we have examined the biodistribution and pharma-
cokinetics of PTX and CER upon administration in PLGA/
PbAE blend nanoparticle formulations in an orthotopic wild-
type (drug sensitive) and drug resistant (MDR-1 positive)
MCF7 estrogen-positive human breast adenocarcinoma model.
While it is known that nanoparticles enhance drug delivery
to tumors by the EPR effect, it is unknown whether MDR
physiology has any further effect on tumor drug disposition
and retention. These studies, therefore, can allow for an
interpretation of the effect of cellular mechanisms of MDR
on tumor targeting of the drugs with blend nanoparticles.
Materials and Methods
1. Preparation and Characterization of Nanoparticle
Formulations. Polymer-blend nanoparticles were manufac-
tured by blending PLGA (MW 12 kDa, 50:50 molar ratio
of lactide to glycolide) (Birmingham Polymers, Pelham, AL)
with PbAE [MW 10 kDa kindly supplied by S.L. (University
of Pittsburgh, Pittsburgh, PA)], in a weight ratio of 70%:
30%, respectively, using solvent displacement. PTX was
loaded at 2.5% (w/w) and CER at 10% (w/w) in the blend
nanoparticles. In addition, the nanoparticles were coloaded
with 20 µCi of
3H-PTX per mg of regular PTX and 2.5 µCi
of
14C-CER per mg of regular CER. The radiolabeled
derivatives of PTX and CER were purchased from American
Radiolabeled Chemicals (St. Louis, MO).
Furthermore, for in ViVo imaging studies, 20 µgo f
rhodamine-PTX per mg of regular PTX was also coloaded
into the nanoparticles. PCL or PLGA was dissolved in
acetone together with 20% (w/w) Pluronic F-108 and CER,
while PbAE was dissolved in ethanol together with PTX.
Both preparations were heated at 37 °C to facilitate dissolu-
tion, after which they were joined and instantaneously added
to 10 volumes of water at pH 8.0 with rapid magnetic stirring
at a rate of 2 mL/min. Polymer-drug complexes were
dissolved in their respective organic phases at 10 mg of total
nanoparticle mass/0.5 mL of organic solvent, using equal
amounts of acetone and ethanol. Following overnight stirring
to allow for evaporation of the organic solvents, nanoparticles
were collected by centrifugation at 10,000 rpm for 40 min
at 4 °C, washed with deionized distilled water adjusted to
pH 8.0, and stored wet at 4 °C. Alongside, free drug
formulations using Cremophore EL and ethanol were pre-
pared, with similar addition of 20 µCi of
3H-PTX per mg of
regular (cold) PTX, 2.5 µCi of
14C-CER per mg of regular
CER, and 20 µg of rhodamine-PTX per mg of regular PTX.
Thus, hereby, for each dose administered, the animals
received radioactive tracers of 1 µCi of
3H-PTX and 0.5 µCi
of
14C-CER, and a ﬂuorescent tracer of 1 µg of rhodamine-
PTX.
Nanoparticles were characterized for size and zeta-potential
on a Brookhaven Zeta-PALS analyzer that combines dynamic
light scattering for size approximation with zeta-potential
analysis (Brookhaven instruments Inc., Holtsville, NY). To
determine a drug release proﬁle for PTX and CER from the
nanoparticles, 10 mg of lyophilized drug-loaded nanoparticles
were initially resuspended in 5 mL of PBS at pH 7.4 and
incubated at 37 °C for 6 h with constant agitation. Every
hour, nanoparticles were centrifuged at 10,000 rpm for 10
min, and 4 mL of release media was removed for analysis
and replaced with 4 mL of PBS pH 7.4 to maintain sink
conditions. At the 6 h time point, the pH of the release
medium was spiked to 6.5 with HCl, after which the particles
continued to incubate under constant agitation. Again, 4 mL
samples of release media were removed at every hour, only
now replaced with PBS at pH 6.5, and the particles were
left to incubate for up until 12 h after the start of the study.
PTX loading yield and subsequent release were determined
by quantitating the amount of PTX by reverse-phase HPLC
on a C18 column using 50% acetonitrile:50% phosphate
buffer with 20 mM SDS as the mobile phase. To quantita-
tively track CER, a ﬂuorescent derivative of CER, namely
NBD-CER (Invitrogen Corporation, Carlsbad, CA), was
loaded into the nanoparticle formulation at 1% w/w, thereby
allowing for quantitation as loading yield and subsequent
release by ﬂuorescent absorption using 485 nm excitation
and 535 nm emission. Studies were repeated thrice.
2. In Vitro Drug Efﬁcacy Studies. Human breast adeno-
carcinoma (MCF7) cells and their multidrug resistant sub-
culture MCF7TR were kindly provided by M.V.S. (Fox Chase
Cancer Center, Philadelphia, PA) and Z.D. (Massachusetts
General Hospital, Boston, MA). The MCF7TR subculture had
been established by successive selection from exposure to
increasing concentrations of paclitaxel, and was found to be
at least 10-fold resistant to paclitaxel over the drug sensitive
(MCF7) culture. To examine the effect of temporal spacing
between administration of PTX and CER on efﬁcacy against
MDR, the MDR cells were plated at 10,000 cells per well
in 96 well plates and treated with 1 µM PTX alone or
alongside 10 µM CER as free drugs in solution, whereby (21) Shenoy, D. B.; Amiji, M. M. Int. J. Pharm. 2005, 293, 261–270.
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administered witha6hdelay following CER, or CER was
administered witha6hdelay following PTX. Since PTX is
a cell-cycle speciﬁc cytotoxic agent, the treatment was left
to proceed for 5 days to ensure that all cells underwent
mitosis. Following this incubation period, cell kill efﬁcacy
was measured by the MTS assay (Promega Corp., Madison,
WI). Treatment with cell culture media was used as a
negative control (0% cell death), while treatment with 100
µg/mL poly(ethyleneimine) was used as a positive control
(100% cell death).
3. In ViWo Biodistribution and Pharmacokinetic Stud-
ies. (a) Animal Model. Female nu/nu (athymic) mice
(Charles River Laboratories, Wilmington, MA) were housed
in sterile cages with ad libitum access to sterile food and
acidiﬁed water on a 12:12 light:dark cycle. All experiments
were approved by the Institutional Animal Care and Use
Committee, the Radiation Safety Committee, and the Ofﬁce
of Environmental Health and Safety of Northeastern
University.
In order to establish and maintain MCF7 estrogen-
responsive tumor in ViVo, estradiol-containing silastic im-
plants were surgically inserted along the right ﬂank of mice
that would receive either wild-type (MCF7) or drug resistant
(MCF7TR) tumor xenografts. For this procedure, mice were
anesthetized by inhalation of a 40% isoﬂurane solution in
USP quality mineral oil by the open drop method, and kept
under anesthesia through a nose cone apparatus that admin-
istered a 30% isoﬂurane solution in mineral oil. A 5.0 mm
incision was made between the scapula, and the subcutaneous
implant was inserted longitudinally. The incision was then
closed with 4-0 nylon sutures, and animals were allowed to
rest and recover for at least 48 h.
(b) Orthotopic Tumor Model Development. To inoculate
MCF7 or MCF7TR cells into the mammary fat pad for
orthotopic tumor development, cultured cells were harvested
and counted. For each mouse, 2 × 10
6 cells were resus-
pended into 100 µL of serum supplemented RPMI, to which
100 µL of Matrigel HC (BD Biosciences, San Jose, CA)
was mixed in. This mixture was injected subcutaneously into
the mammary fat pad of lightly anesthetized animals using
a 27 gauge, 1/2 in. needle, after which animals were left to
rest until tumors reached a palpable volume of 100 mm
3.
Median tumor volume was around 140 mm
3, and animals
that showed any physical characteristics of poor health (such
as weight loss) or had dormant tumors lacking continuous
growth were excluded from the study.
(c) In ViWo Administration. Once the tumor mass reached
a palpable size of 100 mm
3, mice were randomly assigned
to treatment with either PTX + CER in polymer-blend
nanoparticles or PTX + CER as free drug (aqueous solution
obtained by diluting the drugs from Cremophore EL:ethanol
mixture), subdivided into groups of four mice per time point
for a total of four time points (30 min, 1 h, 6 h, 12 h) per
treatment group per tumor type. Each tumor bearing animal
received a single dose intravenous injection (through the tail
vein) of nanoparticle or free drugs at 1 µCi of PTX, and 0.5
µCi of CER diluted in sterile saline at an injection volume
of 500 µL. At the conclusion of the biodistribution time
points, mice were euthanized by CO2 inhalation. Blood was
collected by cardiac puncture, after which in ViVo drug
distribution was rapidly imaged by tracking the ﬂuorescent
output of rhodamine-PTX using a 565/690 nm ﬁlter set on
a Kodak In ViVo FX Imaging Station (Rochester, NY).
(d) Radioactivity Analysis. Following this, blood, tumor,
liver, spleen, kidney, lung, and heart were harvested and
collected into preweighed test tubes. Tissue samples were
homogenized at 10% (w/v) concentration in deionized
distilled water, and 100 µL of tissue homogenate or blood
was added into scintillation vials. Each sample was then
digested in 1.0 mL of Scintigest tissue solubilizer (Thermo
Fisher Scientiﬁc, Waltham, MA) at 55 °C for 2 h, followed
by the addition of 200 µL of 30% (v/v) hydrogen peroxide
(Thermo Fisher Scientiﬁc, Waltham, MA). This preparation
was further incubated at 55 °C for 30 min, after which each
sample received 10 mL of ScintiVerse scintillation ﬂuid
cocktail (Thermo Fisher Scientiﬁc, Waltham, MA). The
samples were further left to quench in the dark for at least
2 h, after which counts of
3H and
14C were measured on an
R/  scintillation counter. Scintillation counting for the free
drug and nanoparticle doses administered was performed
simultaneously to minimize variability. The results were
expressed as percent of administered dose per gram of tissue
or percent of administered dose per mL of blood.
Tumor and blood pharmacokinetic results were analyzed
according to a noncompartmental pharmacokinetic model to
determine mean retention time (MRT), half-life (T1/2), volume
of distribution (Vd), total body clearance (Clt), elimination
rate constant (K), and area under the curve (AUC) for PTX
and CER in tumor and blood.
4. Data Analysis. For drug biodistribution and pharma-
cokinetic proﬁling studies, n ) 4 mice/group/time point.
Statistical analysis was performed by using a two-tailed,
Student’s t test assuming equal variance in groups. We
concluded that the differences were statistically signiﬁcant
at p < 0.05.
Results
Although earlier work
6 revealed the potency of a PTX +
CER combination therapy to treat MDR ovarian cancer, it
was observed that an important and interesting relationship
existed within the kinetics of dosing PTX and CER. Figure
1 shows intracellular delivery of NBD-labeled CER using
PLGA 70%/PbAE 30% blend nanoparticles in MCF7 and
MCF7TR cells and veriﬁes that cell-kill efﬁcacy increased
signiﬁcantly when CER was administered with a delay of
several hours following PTX administration in MCF7TR cells
(Figure 1b), increasing from 39.1% cell death when the drugs
were coadministered to 52.9% cell death when CER was
administered 6 h following CER (p < 0.05). Interestingly,
this increase was not observed when PTX was administered
with a 6 h delay following CER (38.8% cell death) in this
cell line. Additionally, the enhancement of cell-kill with CER
coadministration was not observed in MCF7 (drug sensitive)
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into the formulation, a nanoparticle system was designed that
could simultaneously carry both the PTX and CER thera-
peutics, but release each in a controlled manner within the
tumor cells. To achieve this temporally controlled release,
PLGA was blended with a pH-responsive polymer, PbAE,
at a ratio of 70% to 30% respectively. Table 1 summarizes
the characterization of these particles. The particles were
found to have an average size around 200 nm and a negative
surface charge expected for the PLGA matrix. PTX and CER
were loaded into the particles at 2.5% (w/w) for PTX and
10% (w/w) for CER to ensure preservation of the molar
dosing ratio examined in in Vitro studies (Figure 1) without
compromising particle size or stability. At this load, loading
yield was 100% for both drugs as determined by quantitative
analysis of PTX and CER. The intention of this formulation
was for PTX speciﬁcally to be localized with PbAE for
immediate pH-responsive release upon internalization of the
nanoparticles in the acidic tumor environment (pH 6.5). CER
then was intended to incorporate within the PLGA regions
of the nanoparticle for a slower, more sustained release,
unaffected by the drop in pH at the tumor site. Thereby, the
rapid release of PTX and the slower release of CER would
impart the temporal controlled release proﬁle that results in
enhanced efﬁcacy against MDR cancer. In Vitro release
simulations (Table 1) revealed just that: PTX experienced a
surge in release upon a drop in pH to 6.5, while CER release
remained unaffected when the pH decreased from 7.4
(physiological) to 6.5 (tumor). When the nanoparticles were
incubated in PBS at pH 7.4, a similar amount of PTX and
CER was relased in a one hour span (10.3% PTX and 12.3%
CER). However, when the pH on the nanoparticles was
dropped to 6.5 to mimic internalization into the tumor
Figure 1. (a) Fluorescence microscopic evaluation of NBD-labeled C6-ceramide (CER) delivery in MCF7 (drug
sensitive) and MCF7TR (drug resistant) human breast adenocarcinoma cells. (b) Cell-kill efﬁcacy of kinetic dosing
between paclitaxel (PTX) and CER in MCF7 and MCF7TR cells when PTX was administered at t ) 0, with CER
administration at t ) 6 h, or when CER is administered at t ) 0, with PTX administration at t ) 6h( n ) 8 samples/
treatment).
Table 1. Characterization of the 70% PLGA/30% PbAE
Polymer-Blend Nanoparticles for Physical Attributes, Drug
Load, and Drug Release
Physical Characterization
size (nm) 208.2 ( 5.7
zeta potential (mV) -26.9 ( 5.4
Drug Encapsulation Efﬁcacy
% entrapment % yield
paclitaxel 2.5 100
C6-ceramide 10 100
In Vitro Drug Release (% Release in 1 h)
pH 7.4 pH 6.5
paclitaxel 10.3 ( 0.3 31.9 (1.0
C6-ceramide 12.3 ( 1.7 7.6 (1.3
articles Van Vlerken et al.
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1 h) while the rate of CER release remained unchanged (7.6%
in 1 h). These results verify that PTX release preceded that
of CER by this pH-responsive trigger. With this formulation
intact now, the effects on PTX and CER pharmacokinetics
and biodistribution were examined.
To achieve a direct comparison between PTX and CER
drug biodistribution and pharmacokinetics when administered
as a conventional Cremophore EL-ethanol formulation versus
encapsulation within the 70% PLGA/30% PbAE polymer-
blend nanoparticles, both preparations were spiked with
radiolabeled derivatives of PTX and CER. Both
3H-PTX and
14C-CER were encapsulated within the nanoparticle and free
drug formulations as described in Materials and Methods in
such a way that each animal received a tracer of 1.0 µCi of
PTX and 0.5 µCi of CER of which the counts could be
simultaneously read on an R/ - scintillation counter. Fur-
thermore, to qualitatively assess drug biodistribution, and
particularly tumor localization, resulting from the dose
formulation, both the free drug and nanoparticle forms of
drug were additionally spiked with a red-ﬂuorescent deriva-
tive of PTX (rhodamine-PTX), which could be visualized
in ViVo using an in ViVo imaging module.
Quantitative data was obtained by standardizing
3H and
14C cpm from individual tissues or blood by the counts-per-
minute (cpm) for the dose administered per gram of tissue
or mL of blood, to express tissue and blood drug levels over
time as % of dose/g or mL. Figure 2a depicts the blood and
tumor pharmacokinetic curves for both PTX and CER
resulting from administration as free drug as compared to
PbAE/PLGA blend nanoparticle delivery in mice bearing
MCF7 drug sensitive orthotopic tumor xenografts. As
expected, the data shows that nanoparticle delivery prolongs
plasma retention of PTX over free drug administration,
indicated by a 2-fold increase in PTX from nanoparticle
delivery over free drug (1.02 ( 0.25 versus 0.46 ( 0.08%
dose/mL respectively, p < 0.05). Similarly, tumor retention
of PTX increases signiﬁcantly with nanoparticle delivery of
the drug, whereby at 12 h out 6.5-fold more PTX resides in
the tumor mass compared with the free drug administration
(0.53 ( 0.08 versus 0.08 ( 0.02%/g of nanoparticle versus
free PTX, p < 0.001). What is more striking is that while
Figure 2. (a) Quantitative blood and tumor and (b) qualitative tumor biodistribution and pharmacokinetic proﬁle of
paclitaxel (PTX) and C6-ceramide (CER) administered intravenously as free drug and upon encapsulation in
poly(ethylene oxide)-surface modiﬁed poly(D,L-lactic-co-glycolic acid)/poly(beta-amino ester) [70:30% (w/w)]
polymer-blend nanoparticle (NP) at 1, 6, and 12 h after administration to MCF7 (drug sensitive) tumor bearing mice.
The symbols * and ** indicate statistical signiﬁcance (p < 0.05 and p < 0.001, respectively) between NP and free
drug treatment of each drug (n ) 4 samples/group). The arrows indicate the tumor site as located on photographic
images.
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signiﬁcantly, the nanoparticles cause signiﬁcant CER ac-
cumulation at the tumor site, initially a 2-fold increase early
on at 1 and 6 h, elevating to a 4.5-fold increase by 12 h.
Additionally, the maximal concentration of drug at the tumor
site within this therapeutic window reaches a signiﬁcantly
higher peak with nanoparticle delivery over the free drug
formulation (2.6 ( 0.4 versus 1.42 ( 0.5), a phenomenon
that perhaps explains the efﬁcacy seen with CER treatment
alone. Qualitative biodistribution images that traced red-
ﬂuorescent PTX (Figure 2b) similarly revealed that while
drug accumulation can be observed in tumors of mice
subjected to free drug treatment 6 h out, this signal is lost
by 12 h. However, the mice subjected to nanoparticle
treatment retain their tumor accumulation signal beyond 6 h
to retain visibility even at 12 h out. This result further
suggests that the nanoparticles are retained for prolonged
periods of time in the tumor mass.
Similar results were seen in the blood and tumor phar-
macokinetic proﬁles of PTX and CER when administered
to MCF7TR tumor bearing mice (Figure 3a). While nano-
particle delivery had no effect on blood retention of CER
over free drug administration, PTX retention in the blood
resulting from nanoparticle delivery elevated signiﬁcantly
2- to 2.5-fold over that of free drug, for example to reach
levels of 1.08 ( 0.16 versus 0.43 ( 0.11%/mL at 12 h from
nanoparticle versus free drug administration respectively.
Similar to the trend seen in the drug sensitive MCF7 tumor
bearing mice, nanoparticles elevated not only PTX ac-
cumulation in the tumor mass 2-fold (0.15 ( 0.01 versus.
0.07 ( 0.00 at 12 h, p < 0.001), but particularly CER
accumulation and maximal concentration (1.7 ( 0.13 versus
0.75 ( 0.1 at 6 h, p < 0.001). Figure 3b depicts qualitative
biodistribution images for the MCF7TR tumor bearing mice
that once more revealed that while drug accumulation can
be observed in tumors of mice administered free drug 6 h
out, this signal is lost by 12 h, while the mice subjected to
nanoparticle treatment retain their tumor accumulation signal
at both 6 and 12 h out.
Analysis of tumor and blood pharmacokinetic data by
noncompartmental pharmacokinetics revealed how nanopar-
ticle drug delivery altered key pharmacokinetic parameters
for both PTX and CER. Table 2 and Table 3 summarize the
pharmacokinetic parameters of PTX and CER from free drug
administration and nanoparticle delivery in blood (plasma)
and tumor respectively. As suggested by the plots in Figure
Figure 3. (a) Quantitative blood and tumor and (b) qualitative tumor biodistribution and pharmacokinetic proﬁle of paclitaxel
(PTX) and C6-ceramide (CER) administered intravenously as free drug and upon encapsulation in poly(ethylene
oxide)-surface modiﬁed poly(D,L-lactic-co-glycolic acid)/poly(beta-amino ester) [70:30% (w/w))] polymer-blend nanoparticle
(NP) at 1, 6, and 12 h after administration MCF7TR (MDR) tumor bearing mice. The symbol ** indicates statistical
signiﬁcance (p < 0.001) between NP and free drug treatment of each drug (n ) 4 samples/group). The arrows indicate the
tumor site as located on photographic images.
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the-curve (AUC) in blood, for PTX but not for CER (Table
2). While mean retention time (MRT), the elimination
constant (K), half-life (T1/2) and volume of distribution (Vd)
appeared unchanged for either drug between free drug
administration and nanoparticle delivery in the blood, nano-
particles did signiﬁcantly lower the rate of total body
clearance (Clt) for PTX, albeit not for CER, thereby
supporting the idea that nanoparticles promote prolonged
PTX retention in the blood. Oppositely, though, nanoparticles
promoted a signiﬁcantly increased AUC and decreased Clt
for CER in the tumor tissue (Table 3), although at this site
pharmacokinetics of PTX remained unchanged between
nanoparticle versus free drug delivery. Interestingly, though,
it can be concluded from this study that nanoparticle delivery
does beneﬁt both drug treatments, by increasing PTX levels
and prolonging PTX retention in the circulation, and by
increasing CER retention and decreasing CER clearance from
the tumor site.
Lastly, to determine the effects of nanoparticle delivery
of PTX and CER compared with administration of free PTX
and CER on nontarget distribution, drug distribution over
time was monitored in liver, kidney, spleen, lung, and heart,
as illustrated in Figure 4 for MCF7 tumor bearing mice, and
Figure 5 for MCF7TR tumor bearing mice. From this data, it
appears that while nanoparticle delivery does not signiﬁcantly
alter peak concentrations of PTX or CER that accumulate
the examined nontarget organs, nanoparticle delivery does
appear to prolong clearance of either drug from these
nontarget organs. At 6 h postadministration, similar amounts
of PTX and CER could be detected in the liver, kidney,
spleen, lung and heart of mice bearing either drug sensitive
or MDR tumor types. Twelve hours postadministration, traces
of both PTX and CER are nearly undetectable in the liver,
Table 2. Summary of Plasma Noncompartmental Pharmacokinetic Parameters of Paclitaxel (PTX) and Ceramide (CER)
Resulting from Administration as Free Drug as Compared to Delivery in PLGA/PbAE Polymer-Blend Nanoparticles
a
pharmacokinetic parameter PTX PTX nanoparticle CER CER nanoparticle
MCF7:
AUC (% dose·h/mL) 6.9 ( 1.7 10.5 ( 2.1 2.5 ( 0.8 2.9 ( 0.4
MRT (h) 23.9 ( 10.7 25.1 ( 9.3 347.7 ( 107.5 1470 ( 483
K (h
-1) 0.07 ( 0.02 0.05 ( 0.01 0.003 ( 0.001 0.0009 ( 0.0006
T1/2 (h) 16.6 ( 7.4 17.4 ( 6.4 240.9 ( 75.5 1019 ( 335.1
Clt (% dose·h/(% dose/mL)) 0.009 ( 0.002 0.005 ( 0.001 0.12 ( 0.04 0.07 ( 0.01
Vd (% dose/(% dose/mL)) 0.22 ( 0.10 0.14 ( 0.07 36.6 ( 20.7 130.4 ( 48.8
MCF7TR:
AUC (% dose·h/mL) 5.2 ( 0.9 10.2 ( 0.9* 2.27 ( 0.3 2.9 ( 0.1
MRT (h) 115.4 ( 43.3 54.0 ( 19.6 166.7 ( 90.1 182.5 ( 25.1
K (h
-1) 0.007 ( 0.004 0.020 ( 0.007 0.007 ( 0.005 0.004 ( 0.001
T1/2 (h) 80.0 ( 30.0 37.4 ( 13.6 115.5 ( 62.5 126.5 ( 17.4
Clt (% dose·h/(% dose/mL)) 0.010 ( 0.001 0.005 ( 0.000* 0.09 ( 0.01 0.07 ( 0.00
Vd (% dose/(% dose/mL)) 1.4 ( 0.6 0.25 ( 0.06 17.8 ( 11.2 12.8 ( 1.8
a AUC ) area under the curve; MRT ) mean residence time; K ) elimination rate constant; T1/2 ) half-life; Clt ) total body clearance; Vd
) volume of distribution. The symbols * indicate statistical signiﬁcance (p < 0.05) between free drug and nanoparticle dosage forms for
each drug at the given pharmacokinetic parameter (n ) 3-4 repeats/group).
Table 3. Summary of Tumor Noncompartmental Pharmacokinetic Parameters of Paclitaxel (PTX) and Ceramide (CER)
Resulting from Administration as Free Drug as Compared to Delivery in PLGA/PbAE Polymer-Blend Nanoparticles
a
pharmacokinetic parameter PTX PTX nanoparticle CER CER nanoparticle
MCF7:
AUC (% dose·h/g) 4.9 ( 2.3 6.0 ( 1.0 9.0 ( 0.9 22.5 ( 0.9**
MRT (h) 114.7 ( 53.0 308.4 ( 119.0 39.0 ( 13.8 43.9 ( 6.7
K (h
-1) 0.011 ( 0.005 0.005 ( 0.002 0.04 ( 0.02 0.024 ( 0.004
T1/2 (h) 79.5 ( 36.7 213.7 ( 82.5 27.0 ( 9.5 30.4 ( 4.7
Clt (% dose·h/(% dose/g)) 0.017 ( 0.006 0.009 ( 0.001 0.023 ( 0.003 0.008 ( 0.000*
Vd (% dose/(% dose/g)) 3.7 ( 1.6 2.9 ( 1.2 0.9 ( 0.3 0.39 ( 0.07
MCF7TR:
AUC (% dose·h/g) 2.9 ( 0.6 3.2 ( 0.5 6.47 ( 0.5 11.0 ( 0.9**
MRT (h) 81.7 ( 67.9 153.0 ( 117.8 5.9 ( 0.4 6.5 ( 0.2
K (h
-1) 0.05 ( 0.02 0.02 ( 0.01 0.17 ( 0.01 0.15 ( 0.00
T1/2 (h) 56.6 ( 47.0 106.0 ( 81.6 4.1 ( 0.2 4.5 ( 0.1
Clt (% dose·h/(% dose/g)) 0.019 ( 0.004 0.02 ( 0.002 0.031 ( 0.002 0.018 ( 0.001**
Vd (% dose/(% dose/g)) 2.19 ( 2 3.1 ( 2.5 0.19 ( 0.03 0.12 ( 0.01
a AUC ) area under the curve; MRT ) mean residence time; K ) elimination rate constant; T1/2 ) half-life; Clt ) total body clearance; Vd
) volume of distribution. The symbols * and ** indicate statistical signiﬁcance (p < 0.05 and p < 0.001, respectively) between free drug and
nanoparticle dosage forms for each drug at the given pharmacokinetic parameter (n ) 3-4 repeats/group).
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clearance of the majority of the administered drug. However,
nanoparticle delivery of both PTX and CER are retained at
a signiﬁcantly higher level in these tissue types by 12 h
postadministration. Curiously, though, this effect is only
observed in mice bearing the MCF7 tumor type, while no
differences exist between nanoparticle and free drug retention
at 12 h for the MCF7TR tumor bearing mice. Although a
prolonged retention at nontarget tissues could be a factor
for toxicity, extensive studies examining white blood cell
counts and liver enzyme activity following both acute and
chronic administration of this nanoparticle therapy revealed
that the therapy was well tolerated since no such toxicity
arises (data not shown).
Discussion
It is widely known that nanoparticles are beneﬁcial tumor
targeting vehicles due to their passive targeting properties
by the enhanced permeability and retention (EPR) effect,
whereby the added advantage of stealth shielding the particles
with a poly(ethylene glycol/oxide) (PEO/PEG) surface
modiﬁcation avoids uptake by the reticuloendothelial system,
thereby improving circulation time of the nanoparticles.
22
The formulation described herein is for a blend of slow
releasing PLGA and pH-responsive rapid releasing PbAE
for temporal controlled release of PTX with CER to treat
MDR cancer, whereby the nanoparticle was surfaced modi-
ﬁed with PEO to promote stealth shielding and prolonged
circulation of the combination drug therapy. Using radiola-
beled derivatives of PTX and CER, namely
3H-PTX and
14C-
CER, it was possible to quantitatively track drug distribution
over time in ViVo resulting from administration as free drug
versus encapsulation within the polymer-blend nanoparticles.
Drug distribution was monitored in mice bearing either
drug sensitive MCF7 or MDR MCF7TR tumors, since
differences between the physiology of these two tumor types
could potentially lead to differences in drug disposition and
retention at the tumor site speciﬁcally. Surprisingly, there
was no difference in magnitude between the tumor ac-
cumulations at 6 h after administration of free PTX,
nanoparticle PTX, free CER, or nanoparticle CER between
the drug sensitive and MDR tumors. Beyond 6 h, levels of
PTX and CER delivered by nanoparticles remained un-
changed in the MCF7 tumors, while levels of PTX and CER
delivered as free drug began to decrease. Overall, the amount
of tumor accumulation of both drugs administered in
nanoparticles signiﬁcantly exceeded that of free drug ad-
ministration at some of the tested time points in the MCF7
tumor bearing animals. This ﬁnding supports the hypothesis
of enhanced tumor accumulation and retention of nanopar-
ticle-delivered drugs by the EPR effect.
20 However, the
effects seen in the MDR MCF7TR tumors were very different.
While the magnitude of drug accumulation between the two
tumor types was no different, intratumoral levels of PTX
and CER from both free drug and nanoparticle administration
tumors dropped drastically in the MCF7TR after6ht onearly
entirely disappear from the tumor by 12 h after administra-
(22) Gref, R.; Minamitake, Y.; Peracchia, M. T.; Trubetskoy, V.;
Torchilin, V.; Langer, R. Science 1994, 263 (5153), 1600–1603.
Figure 4. Quantitative tissue biodistribution proﬁle of (a)
paclitaxel (PTX) and (b) C6-ceramide (CER) administered
as free drug or in poly(ethylene oxide)-surface modiﬁed
poly(D,L-lactic-co-glycolic acid)/poly(beta-amino ester) [70:
30% (w/w)) polymer-blend nanoparticle formulations at 1,
6, and 12 h after intravenous administration in MCF7 (drug
sensitive) tumor bearing mice.
Figure 5. Quantitative tissue biodistribution proﬁle of (a)
paclitaxel (PTX) and (b) C6-ceramide (CER) administered
as free drug or in poly(ethylene oxide)-surface modiﬁed
poly(D,L-lactic-co-glycolic acid)/poly(beta-amino ester) [70:
30% (w/w)) polymer-blend nanoparticle formulations at 1,
6, and 12 h after intravenous administration in MCF7TR
(drug resistant) tumor bearing mice.
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in the MCF7 tumors. This ﬁnding suggests that drug efﬂux
pumps like P-glycoprotein mediate removal of both PTX and
CER from the MDR tumor after 6 h, although, since only
free drug is susceptible to efﬂux, we cannot conclude that
the drugs must have been released from the nanoparticles
by this time point. Although the amount of nanoparticle-
delivered CER reaching MCF7TR tumors exceeded the
amount of CER administered as free drug by 2-fold, similar
to the results seen in the MCF7 tumors, we did not observe
this increase in PTX delivered as free drug versus nanopar-
ticles. However, this result is in accordance with the
prediction that the bulk of PTX releases immediately from
this nanoparticle upon internalization into the tumor environ-
ment from a drop in pH. Unfortunately, the presence of
P-glycoprotein efﬂux pumps appears to quickly remove the
released PTX from the tumor site. Nevertheless, the results
still support the increased tumor accumulation of nanoparticle
delivered drugs by the EPR effect in the MCF7TR tumors as
well, although retention of the drugs in the tumor site is
hindered by the P-glycoprotein mediated efﬂux. The systemic
pharmacokinetic parameters of CER administered as free
drug or nanoparticles were very similar in magnitude and
proﬁle between MCF7 and MCF7TR tumor bearing mice.
Interestingly, in both animal models, plasma CER does not
display a proﬁle characteristic of instantaneous input. Rather,
CER blood pharmacokinetics exhibit proﬁles that are more
representative of oral absorption. Although the hydrophobic-
ity of free CER may lead to longer residence times at the
site of injection, nanoparticle formulations of CER behave
similarly while not exhibiting such hydrophobicity. It is
unlikely that CER is prematurely released from the nano-
particle to linger at the injection site, since tumor pharma-
cokinetic results imply that CER is retained in the nanopar-
ticle by 6 h after administration. Since tumor and nonspeciﬁc
target accumulation of CER follows a similar proﬁle as PTX,
with peak accumulation at 1 h after administration (with the
exception of MCF7TR tumors, where peak accumulation
occurred at 6 h), it is again unlikely that peak CER plasma
levels take place prior to 30 min after administration.
Unfortunately, the pharmacokinetics of CER and other
sphingolipids following intravenous administration have not
been evaluated to date by other groups, forbidding conclusive
statements regarding plasma CER pharmacokinetics. Thus,
at this point, it can merely be speculated that CER perhaps
resides on the surface of the nanoparticle rather than
internally to behave more like free CER in the circulation.
This could cause CER of either formulation to linger at the
injection site or sequester in more lipophilic compartments.
Systemic pharmacokinetics of PTX, on the other hand,
behaved similarly to the pharmacokinetic proﬁle obtained
in other studies,
16 and displayed a proﬁle characteristic of
instantaneous input whereby peak concentration occurred at
the time of injection, with a subsequent disappearance of
PTX from the plasma over time. In both the MCF7 and
MCF7TR tumor bearing mice, PTX administration as free
drug peaked upon administration, with a gradual decrease
over time to culminate at nearly undetectable levels by 12 h
after administration. Nanoparticle administration, on the other
hand, caused a prolonged retention of PTX in the circulation
of both MCF7 and MCF7TR tumor bearing mice seen by the
increased amount of drug present in the circulation at 6 h
after administration, compared to the amount of free drug
present at this time point. Although it appears that PTX
retention is more prominent in the MCF7TR tumor bearing
mice over MCF7 tumor bearing mice, the magnitude of
plasma drug level between these two animal models is very
similar throughout all time points. These results are sup-
portive of the known effects of PEO-surface modiﬁcation
on nanoparticles to produce prolonged circulation by stealth
shielding, and agree well with the blood and tumor phar-
macokinetic proﬁle determined for PTX from free drug
administration and nanoparticle delivery in SKOV3 tumor
bearing mice.
15
An evaluation of nonspeciﬁc target accumulation revealed
that PTX administration in nanoparticles did not signiﬁcantly
alter nontarget accumulation over that of free drug, with
neither an increase nor a decrease in drug retention in the
most perfused tissues. This result is identical to similar
studies conducted for nanoparticle versus free drug ac-
cumulation of PTX at nonspeciﬁc sites.
23 Although other
studies have reported a decreased accumulation in liver,
spleen, and lung resulting from nanoparticle administration,
24
we did not observe such results. On the other hand, although
CER does not accumulate to any greater amount in nontarget
tissues between free drug and nanoparticle administration,
the nanoparticle dosage form does result in a prolonged
retention of CER in all ﬁve nontarget tissues examined, liver,
kidney, spleen, lung, and heart. It should be noted that this
result was only seen in the MCF7 tumor bearing mice, while
not in the MCF7TR tumor bearing mice. Given this incon-
sistency, it is uncertain whether CER truly is retained in
nonspeciﬁc tissues for a prolonged period of time, since it
is unlikely that the physiological differences between tumors
would affect nontarget drug disposition.
Nevertheless, not only do the results demonstrate that
nanoparticle delivery enhances tumor accumulation of drugs,
supporting the well-known characteristic of nanoparticle
tumor targeting by the EPR effect, but more importantly,
the results demonstrate the effect that MDR tumor physiology
may have on drug disposition at the target site despite EPR
targeting. This knowledge could help factor into the design
of nanoparticle platforms to enhance tumor targeting even
in the presence of physiological barriers such as the presence
of P-glycoprotein.
Conclusions
Long-circulating PEO-modiﬁed nanoparticles have been
shown to accumulate preferentially in the solid tumor upon
(23) Zhang, C.; Qu, G.; Sun, Y.; Wu, X.; Yao, Z.; Guo, Q.; Ding, Q.;
Yuan, S.; Shen, Z.; Ping, Q.; Zhou, H. Biomaterials 2008, 29
(9), 1233–1241.
(24) Yang, T.; Cui, F. D.; Choi, M. K.; Cho, J. W.; Chung, S. J.; Shim,
C. K.; Kim, D. D. Int. J. Pharm. 2007, 338 (1-2), 317–326.
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VOL. 5, NO. 4 MOLECULAR PHARMACEUTICS 525systemic administration. In this study, we have examined
the delivery of combination PTX and CER to modulate the
apoptotic threshold in tumor MDR by formulating both of
these drugs in a single PLGA/PbAE (70:30 by weight) blend
nanoparticles. When administered in an orthotopic (drug
sensitive) MCF7 and multidrug resistant MCF7TR human
breast adenocarcinoma model established in the mammary
pad of female nu/nu mice, the nanoparticle-mediated delivery
enhanced circulating times in ViVo and allowed passive
targeting to the tumor mass. The pharmacokinetic analysis
revealed a trend for nanoparticle-mediated delivery of PTX
toward the reduced clearance of the drug from the systemic
circulation and tumor mass. We anticipate that the decreased
PTX clearance would have signiﬁcant implication in the
treatment of MDR tumors. Overall, these results are encour-
aging for the development of multifunctional nanoparticle
systems that can deliver combination therapy for synergistic
effects, especially in refractory diseases.
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